Genetron Health to Highlight Data from 18 Studies at ESMO 2020
September 18 2020 - 6:00AM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening and companion diagnostics development, and its
collaborators will present data from 18 studies at the upcoming
European Society for Medical Oncology (ESMO) Virtual Congress 2020
taking place on September 19-21.
The abstracts include 15 studies on
translational medicine covering various cancer types and three
studies on bioinformatics development. Data that will be
highlighted at the ESMO Virtual Congress were generated in
collaboration with more than 10 notable cancer centers and clinical
hospitals in China. In summary, the abstracts are grouped by four
topics as follows:
Chinese population’s genetic
characteristics:
- Six studies (#3835, #3836, #3898, #3946, #3961, #3965) focus
mainly on the characteristic analyses of high-frequency gene
mutations and gene rearrangements in the Chinese population. These
studies aim at gathering specific data for the Chinese population
in order to design precision oncology therapies for the domestic
market.
- Three studies (#3434, #3915, and #3938) describe the genetic
characteristics such as germline mutations, somatic mutations and
precision treatment targets in Chinese patients with pancreatic
ductal adenocarcinomas.
Immunotherapies:
- Two studies (#3943 and #4313) focus on the exploration of
immunotherapy-associated molecular biomarkers. The Company has
found that KMT2C/KMT2D genetic alterations can be used as
prognostic indicators for immunotherapy in colorectal cancer and
gastric cancer.
- One study (#4161) demonstrates the therapeutic potential of
preoperative immunotherapy in combination with chemotherapy for
patients with metastatic pancreatic ductal adenocarcinomas.
Biomarker discoveries:
- One study (#3888) uncovered tumor type-specific genetic
variations that could serve as biomarkers for prognosis and
perioperative monitoring in each tumor type.
- Two studies (#3845 and #4127) evaluated the clinical
significance of ONECUT2 gene methylation in the prognosis
and diagnosis of upper tract urinary carcinoma.
Optimizing bioinformatics:
- One study (#3771) discusses the
establishment of genomic database and bioinformatic workflow to
help detect somatic mutations more precisely in the low mappable
regions of human genome. One study (#3827) focuses on the utility
of HRD detection using somatic mutation patterns, while another
study (#3797) reveals that activity of Wnt may be an independent
negative prognostic predictor of survival in patients with low
grade gliomas. In addition, a set of key feature genes was selected
and can be used in clinical setting for prognosis of patients with
low grade gliomas.
“We are pleased to showcase our data from 18
research studies at the upcoming ESMO Virtual Congress. These data
reflect Genetron Health’s broad research focus and capabilities in
various cancer types including lung, gastrointestinal, brain, upper
tract urinary and others. Additionally, we have advanced our
research in understanding certain genomic characteristics of the
Chinese population, target selections and validations, as well as
further optimization of our bioinformatics,” remarked Hai Yan, PhD,
the Company’s Co-founder and Chief Scientific Officer. “Lung cancer
is one of our key focus areas and both the EGFR fusion and RET
rearrangement studies could help us further in designing panels to
guide clinical treatments. In regards to research studies in
gastrointestinal cancer, KMT2C/D mutation findings could
potentially be beneficial in identifying colorectal cancer patients
for immune checkpoint inhibitor therapies, and gastric cancer
patients for other immunotherapies. Furthermore, our research has
shown that liquid biopsy plus genetic and epigenetic profiling
could help predict the risk of upper tract urinary carcinoma.”
The 18 abstracts include:
Abstract Number |
Title |
3434 |
Comprehensive molecular profiling of pancreatic ductal
adenocarcinoma in Chinese population |
3771 |
BLAST-guided mappability knowledgebase facilitates accurate
detection of somatic variants |
3797 |
Activation of the Wnt/PCP signaling pathway is an adverse
prognostic predictor in patients with low grade glioma (LGG) |
3827 |
Accurate detection of HRD status in multiple cancer types using
somatic mutation pattern |
3835 |
Identification of RET Rearrangement in 12888 Chinese Lung Cancer
Patients by Next-Generation Sequencing (NGS) |
3836 |
A pan-cancer study of GNAQ/GNA11 mutations in Chinese cancer
patients |
3845 |
A multivariate logistic regression model for detection of upper
tract urinary carcinoma in patients with hematuria |
3888 |
The Consistency of Mutation Profiles between Treatment-naïve
Circulating Tumor DNA and Tumor Tissue Mutations in a Multi-Cancer
Monitoring Cohort |
3898 |
Identification of epidermal growth factor receptor (EGFR) Fusions
in a Large Chinese Lung Cancer Population |
3915 |
Deleterious germline mutations in patients with pancreatic ductal
adenocarcinoma |
3938 |
Clinical relevance of somatic and germline alterations in patients
with pancreatic ductal adenocarcinoma |
3943 |
KMT2C/KMT2D (KMT2C/D): Promising Biomarkers for Immunotherapy in
Gastric Cancer |
3946 |
Investigation of Osimertinib-Sensitive EGFR Mutations in Brain
Tumors |
3961 |
The genomic characteristics of JAK family in 11159 Chinese solid
tumor patients |
3965 |
Genomic alterations of KEAP1/NFE2L2/CUL3(K/N/C) in Chinese lung
cancer patients |
4127 |
Identification of the methylated ONECUT2 gene through real-time
methylation-specific polymerase chain reaction assays for the
noninvasive detection of upper tract urinary carcinoma in urine
samples |
4161 |
Nab-paclitaxel plus S1 with or without Sintilimab in metastatic
pancreatic ductal adenocarcinoma: A single center, retrospective
study |
4313 |
Investigating the potential relationship between KMT2C/KMT2D
Mutations and Immune Checkpoint Inhibitor (ICI) in Colorectal
Cancer (CRC) |
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron Health” or the
“Company”) (Nasdaq:GTH) is a leading precision oncology platform
company in China that specializes in cancer molecular profiling and
harnesses advanced technologies in molecular biology and data
science to transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor StatementThis press
release contains forward-looking statements within the meaning of
federal securities laws, including results of the studies on
translational medicine covering various cancer types and studies on
bioinformatics development, which involve risks and uncertainties
that could cause the actual results to differ materially from the
anticipated results and expectations expressed in these
forward-looking statements. These statements are made under the
“safe harbor” provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Statements that are not historical facts,
including statements about the Company’s beliefs and expectations,
are forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”,
“will,” “expect,” “anticipate,” “target,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “potential,” “continue,” “is/are
likely to” or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company’s filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations Contacts US:
Hoki Luk Head of Investor Relations
Email: hoki.luk@genetronhealth.com Phone: +1 (408)
891-9255
Stephanie Carrington Westwicke, an ICR Company
Email: Stephanie.Carrington@westwicke.com Phone: +1 (646)
277-1282
Asia: Bill Zima ICR, Inc.
Email: bill.zima@icrinc.com GenetronIR@icrinc.com
Media Relations Contact Edmond
Lococo ICR Edmond.Lococo@icrinc.com Mobile: +86 138-1079-1408
genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024